Alderbio Holdings LLC

H. Lundbeck A/s

Vitaeris Inc.

Katie Olson

John A Latham

Leon F Garcia-Martinez

Brian Robert Kovacevich

Anne Elisabeth Carvalho Jensen

Ben Dutzar

Jeffrey T L Smith

Ethan Wayne Ojala

Jeffrey Tl Smith

Benjamin H Dutzar

Patricia Dianne McNeill

Jens J Billgren

Danielle Mitchell

John Latham

Maria-Cristina Loomis

Mark Litton

Randall Schatzman

Nicole M Janson

Leon F Garcia-martinez

Anne Elisabeth Carvalho-Jensen

Patricia Dianne Mcneill

Anne Elisabeth Jensen

Leon Garcia-Martinez

Ethan Ojala

Brian Kovacevich

Jeffrey TL Smith

Danielle M Mitchell

Leon Garcia - Martinez

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity

The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

Anti-CGRP compositions and use thereof

The invention relates to the use of anti-IL-6 antibodies or antibody fragments containing a specific epitopic specificity to treat conditions involving elevated Il-6. In some embodiments the anti-IL-6 antibodies contain specific CDRs.

Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments

The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-&#x3b1;. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-TNF-&#x3b1; antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-TNF-&#x3b1; antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-TNF-&#x3b1; antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with TNF-&#x3b1;.

Antibodies to TNF-&#x3b1; and use thereof

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Antibodies to IL-6 and use thereof

Use of anti-IL-6 antibodies having specific binding properties to treat cachexia

Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies

The present invention is directed to antibodies and fragments thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Growing community of inventors

Kenmore, WA, United States of America

Katie Olson